论文部分内容阅读
大多数抗肿瘤药物在发挥其疗效时对宿主的免疫功能也有一定损伤作用,但有些抗肿瘤药物不仅具有满意的抗瘤效果,同时还具有一定的免疫增强作用。已有研究表明,博来霉素(BLM)具有多种免疫增强作用,如激活巨噬细胞毒性,消除抑制T细胞活性及增强T细胞功能。BLM的新衍生物Liblom—ycin(LIB)具有较强的体外抗瘤活性(比BLM约强10倍),但对于皮下瘤(如纤维肉瘤KMT—17)效果较差,在相同治疗条件下,BLM疗效明显强于LIB。本实验研究了腹腔接种KMT—17肿瘤,腹腔给予BLM、Pepl—
Most antitumor drugs play a role in the immune function of the host when exerting their curative effect. However, some antitumor drugs not only have satisfactory anti-tumor effect but also have certain immune enhancement effect. Studies have shown that bleomycin (BLM) has a variety of immune-enhancing effects, such as activation of macrophage cytotoxicity, elimination of T cell inhibition and enhance T cell function. Liblom-ycin (LIB), a new derivative of BLM, has strong in vitro antitumor activity (about 10-fold more than BLM) but is less effective on subcutaneous tumors (eg, KMT-17 fibrosarcoma). Under the same therapeutic conditions, BLM efficacy was significantly stronger than LIB. In this study, intraperitoneal inoculation of KMT-17 tumor, intraperitoneal administration of BLM, Pepl-